Bank of America
MYGN icon

Bank of America’s Myriad Genetics MYGN Stock Holding History

Bank of America’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,400
Closed -$368K – 7361
2015
Q1 		$368K Buy
+10,400
New +$372K ﹤0.01% 4518
2014
Q3 		– Sell
-1,000
Closed -$39K – 8104
2014
Q2 		$39K Sell
1,000
-21,900
-96% -$815K ﹤0.01% 6828
2014
Q1 		$783K Buy
22,900
+13,800
+152% +$428K ﹤0.01% 4157
2013
Q4 		$191K Sell
9,100
-20,900
-70% -$529K ﹤0.01% 5640
2013
Q3 		$705K Buy
+30,000
New +$852K ﹤0.01% 4312

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America's MYGN Position: Q1 2026 in Review

Bank of America reduced its Myriad Genetics (MYGN) stake by 40% in Q1 2026, selling an estimated $1.79M and leaving 523,020 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4007.

Bank of America first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $83.6M in Q1 2021. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Bank of America held 523,020 shares of Myriad Genetics worth $2.35M as of Q1 2026.
  • Bank of America sold 344,051 Myriad Genetics shares in Q1 2026, an estimated $1.79M.
  • Myriad Genetics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4007 holding.
  • Bank of America first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Myriad Genetics position peaked at $83.6M in Q1 2021.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.